New Leadership Positions Prompt Rally in ROSG

Shares of Rosetta Genomics (NASDAQ:ROSG) climbed 13% Thursday morning after the company announced the hiring of a Chief Medical Officer and Chief Scientific Officer, both newly-created positions. ROSG has been on the decline since mid-September, and we don’t expect Thursday’s rally to catalyze or sustain any long-term gains. The company has been struggling with the commercialization of its line of MiRview oncology assays, but may have recently made strides through a co-promotion agreement with Precision Therapeutics and the ramping up of commercial operations. Short-term, however, ROSG is unlikely to maintain any highs from Thursday’s rally. Even after announcing the domestic launch of the miRview Mets2 assay, the company’s flagship product, on October 2, ROSG experienced only a momentary pop before returning to its downward trend. Long-term success will rely on adoption trends for the company’s diagnostics, which remain to be seen. The company’s next financial report should be revealing of miRview’s sales growth and the company’s efforts to improve commercialization.

Additional disclosure: PropThink is a team of editors, analysts, and writers. Use of PropThink's research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at this link.